Exchange: OTC·Updated 03:54 PM EST

MUEL News

News
all
press releases
The Zacks Analyst Blog Highlights ASML, Alibaba, Intuitive Surgical, Paul Mueller and Presurance
ASML, BABA, ISRG, MUEL and PRHI feature in Zacks reports, highlighting growth drivers, challenges and performance outlooks.
Zacks
The Zacks Analyst Blog Highlights ASML, Alibaba, Intuitive Surgical, Paul Mueller and Presurance
ASML, BABA, ISRG, MUEL and PRHI feature in Zacks reports, highlighting growth drivers, challenges and performance outlooks.
Zacks
More News
Paul Mueller's Q3 earnings surge y/y on industrial equipment demand and improved margins, but declining cash flows and a softer backlog raise concerns.
Zacks
Paul Mueller's Q2 revenues jump 29% y/y, but lower margins weigh on earnings as strong pharmaceutical demand and a healthy backlog support the results.
Zacks
MUEL's Q1 earnings drop sharply y/y despite solid revenue growth, as rising project costs and delays pressure margins and weigh on profitability.
Zacks
MUEL posts strong Q4 results, with rising sales, higher profits and a record backlog, driving shares sharply ahead of the broader market.
Zacks
Discover why Zacks, the first on Wall Street to initiate coverage, rates MUEL as "Neutral." Explore how Paul Mueller's surging backlog and pharma-driven growth are reshaping its revenue outlook amid key execution risks.
Zacks

Advertisement|Remove ads.